Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 6.97B 6.14B 5.7B 5.24B 9.83B 673B 9.99B 67.72B 26.55B 330B 26.18B 25.61B 1,142B P/E 2026 *
-7.31x
P/E 2027 * -175x
Enterprise Value 7.01B 6.17B 5.73B 5.26B 9.88B 677B 10.04B 68.06B 26.68B 332B 26.31B 25.74B 1,148B EV / Sales 2026 *
10.4x
EV / Sales 2027 * 8.48x
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
1 day-1.16%
1 week-3.69%
Current month-3.45%
1 month+1.76%
3 months+22.93%
6 months+19.87%
Current year+43.09%
1 week 109.75
Extreme 109.75
120.54
1 month 109.75
Extreme 109.75
130
Current year 73.82
Extreme 73.82
130
1 year 50.25
Extreme 50.25
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Sell

Chief Financial Officer

-5,000 0.0082%
7/6/26 Fiscal year

Founder

60,000 0.0984%
7/1/26 Sell

Controller/Auditor

-2,721 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
-1.16%-3.69%+113.06%+336.58% 6.97B
+0.86%+2.30%+49.71%+158.86% 1,057B
+1.59%+5.37%+55.77%+54.77% 624B
+0.95%+1.95%+36.11%+80.44% 454B
+1.60%+7.09%+35.90%+29.32% 341B
-0.60%+2.95%+36.28%+39.04% 297B
-0.14%+0.33%+18.70%+17.64% 262B
+0.09%-4.53%-27.60%-42.19% 215B
+1.22%+1.20%+21.61%+60.14% 201B
-1.18%-5.13%+13.87%+60.35% 162B
Average +0.32%+0.44%+35.34%+79.49% 362.09B
Weighted average by Cap. +0.75%+1.56%+36.76%+77.33%

Financials

2026 *2027 *
Net sales 675M 594M 552M 507M 952M 65.2B 968M 6.56B 2.57B 31.96B 2.53B 2.48B 111B 815M 717M 667M 612M 1.15B 78.7B 1.17B 7.92B 3.1B 38.58B 3.06B 2.99B 134B
Net income -910M -800M -744M -683M -1.28B -87.83B -1.3B -8.83B -3.46B -43.06B -3.41B -3.34B -149B -1.62M -1.43M -1.33M -1.22M -2.29M -157M -2.32M -15.75M -6.17M -76.77M -6.09M -5.96M -266M
Net Debt 34.69M 30.52M 28.36M 26.04M 48.88M 3.35B 49.7M 337M 132M 1.64B 130M 127M 5.68B -61.06M -53.73M -49.93M -45.85M -86.05M -5.9B -87.49M -593M -232M -2.89B -229M -224M -10B
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
418
Date Price Change Volume
26-07-24 US$113.03 -1.16% 516,939
26-07-23 US$114.36 -0.10% 1,403,720
26-07-22 US$114.48 -2.20% 441,965
26-07-21 US$117.05 +0.37% 619,528
26-07-20 US$116.62 -1.88% 365,743
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
113.03USD
Average target price
146.50USD
Spread / Average Target
+29.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIRM Stock